<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 19:02:01 -0700</creation_date>
  <update_date>2013-05-27 11:06:12 -0600</update_date>
  <accession>HMDBP02057</accession>
  <secondary_accessions>
    <accession>7536</accession>
  </secondary_accessions>
  <protein_type>Unknown</protein_type>
  <synonyms>
    <synonym>CA-I</synonym>
    <synonym>CAB</synonym>
    <synonym>Carbonate dehydratase I</synonym>
    <synonym>Carbonic anhydrase B</synonym>
    <synonym>Carbonic anhydrase I</synonym>
  </synonyms>
  <gene_name>CA1</gene_name>
  <general_function>Involved in carbonate dehydratase activity</general_function>
  <specific_function>Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB01303</accession>
      <name>Zinc (II) ion</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01967</accession>
      <name>Carbon dioxide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02111</accession>
      <name>Water</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03538</accession>
      <name>Carbonic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01850</accession>
      <name>Verapamil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05018</accession>
      <name>Amlodipine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01928</accession>
      <name>Hydrochlorothiazide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14377</accession>
      <name>Methyclothiazide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14456</accession>
      <name>Ethoxzolamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14567</accession>
      <name>Methocarbamol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14580</accession>
      <name>Bendroflumethiazide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14702</accession>
      <name>Benzthiazide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14744</accession>
      <name>Cyclothiazide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14841</accession>
      <name>Methazolamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14912</accession>
      <name>Hydroflumethiazide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14957</accession>
      <name>Acetazolamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15007</accession>
      <name>Dorzolamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15018</accession>
      <name>Chlorothiazide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15045</accession>
      <name>Zonisamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15156</accession>
      <name>Trichlormethiazide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15165</accession>
      <name>Ethinamate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15251</accession>
      <name>Diazoxide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15275</accession>
      <name>Dichlorphenamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15325</accession>
      <name>Brinzolamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15420</accession>
      <name>Quinethazone</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>cation binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>metal ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transition metal ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>zinc ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>lyase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>carbon-oxygen lyase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>hydro-lyase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>carbonate dehydratase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cellular metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>one-carbon metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intracellular part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cytoplasm</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>cytosol</description>
      <go_id>GO:0005829</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>Golgi apparatus</description>
      <go_id>GO:0005794</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>carbonate dehydratase activity</description>
      <go_id>GO:0004089</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>metal ion binding</description>
      <go_id>GO:0046872</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>zinc ion binding</description>
      <go_id>GO:0008270</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>bicarbonate transport</description>
      <go_id>GO:0015701</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>one-carbon metabolic process</description>
      <go_id>GO:0006730</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>small molecule metabolic process</description>
      <go_id>GO:0044281</go_id>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Cytoplasm</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>8</chromosome_location>
    <locus>8q21.2</locus>
    <gene_sequence>&gt;786 bp
ATGGCAAGTCCAGACTGGGGATATGATGACAAAAATGGTCCTGAACAATGGAGCAAGCTG
TATCCCATTGCCAATGGAAATAACCAATCCCCTGTTGATATTAAAACCAGTGAAACCAAA
CATGACACCTCTCTGAAACCTATTAGTGTCTCCTACAACCCAGCCACAGCCAAAGAAATT
ATCAATGTGGGGCATTCTTTCCATGTAAATTTTGAGGACAACGATAACCGATCAGTGCTG
AAAGGTGGTCCTTTCTCTGACAGCTACAGGCTCTTTCAGTTTCATTTTCACTGGGGCAGT
ACAAATGAGCATGGTTCAGAACATACAGTGGATGGAGTCAAATATTCTGCCGAGCTTCAC
GTAGCTCACTGGAATTCTGCAAAGTACTCCAGCCTTGCTGAAGCTGCCTCAAAGGCTGAT
GGTTTGGCAGTTATTGGTGTTTTGATGAAGGTTGGTGAGGCCAACCCAAAGCTGCAGAAA
GTACTTGATGCCCTCCAAGCAATTAAAACCAAGGGCAAACGAGCCCCATTCACAAATTTT
GACCCCTCTACTCTCCTTCCTTCATCCCTGGATTTCTGGACCTACCCTGGCTCTCTGACT
CATCCTCCTCTTTATGAGAGTGTAACTTGGATCATCTGTAAGGAGAGCATCAGTGTCAGC
TCAGAGCAGCTGGCACAATTCCGCAGCCTTCTATCAAATGTTGAAGGTGATAACGCTGTC
CCCATGCAGCACAACAACCGCCCAACCCAACCTCTGAAGGGCAGAACAGTGAGAGCTTCA
TTTTGA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>261</residue_number>
    <molecular_weight>28870.0</molecular_weight>
    <theoretical_pi>7.117</theoretical_pi>
    <pfams>
      <pfam>
        <name>Carb_anhydrase</name>
        <pfam_id>PF00194</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
    </transmembrane_regions>
    <signal_regions>
    </signal_regions>
    <protein_sequence>&gt;Carbonic anhydrase 1
MASPDWGYDDKNGPEQWSKLYPIANGNNQSPVDIKTSETKHDTSLKPISVSYNPATAKEI
INVGHSFHVNFEDNDNRSVLKGGPFSDSYRLFQFHFHWGSTNEHGSEHTVDGVKYSAELH
VAHWNSAKYSSLAEAASKADGLAVIGVLMKVGEANPKLQKVLDALQAIKTKGKRAPFTNF
DPSTLLPSSLDFWTYPGSLTHPPLYESVTWIICKESISVSSEQLAQFRSLLSNVEGDNAV
PMQHNNRPTQPLKGRTVRASF</protein_sequence>
  </protein_properties>
  <genbank_protein_id>29600</genbank_protein_id>
  <uniprot_id>P00915</uniprot_id>
  <uniprot_name>CAH1_HUMAN</uniprot_name>
  <pdb_ids>
    <pdb_id>1AZM</pdb_id>
    <pdb_id>1BZM</pdb_id>
    <pdb_id>1CRM</pdb_id>
    <pdb_id>1CZM</pdb_id>
    <pdb_id>1HCB</pdb_id>
    <pdb_id>1HUG</pdb_id>
    <pdb_id>1HUH</pdb_id>
    <pdb_id>1J9W</pdb_id>
    <pdb_id>1JV0</pdb_id>
    <pdb_id>2CAB</pdb_id>
    <pdb_id>2FOY</pdb_id>
    <pdb_id>2FW4</pdb_id>
    <pdb_id>2IT4</pdb_id>
    <pdb_id>2NMX</pdb_id>
    <pdb_id>2NN1</pdb_id>
    <pdb_id>2NN7</pdb_id>
    <pdb_id>3LXE</pdb_id>
  </pdb_ids>
  <genbank_gene_id>X05014</genbank_gene_id>
  <genecard_id>CA1</genecard_id>
  <geneatlas_id>CA1</geneatlas_id>
  <hgnc_id>HGNC:1368</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Barlow JH, Lowe N, Edwards YH, Butterworth PH: Human carbonic anhydrase I cDNA.  Nucleic Acids Res. 1987 Mar 11;15(5):2386.</reference_text>
      <pubmed_id>3104879</pubmed_id>
    </reference>
    <reference>
      <reference_text>Lowe N, Brady HJ, Barlow JH, Sowden JC, Edwards M, Butterworth PH: Structure and methylation patterns of the gene encoding human carbonic anhydrase I. Gene. 1990 Sep 14;93(2):277-83.</reference_text>
      <pubmed_id>2121614</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Giraud N, Marriq C, Laurent-Tabusse G: [Primary structure of human B erythrocyte carbonic anhydrase. 3. Sequence of CNBr fragment I and III (residues 149-260)] Biochimie. 1974;56(8):1031-43.</reference_text>
      <pubmed_id>4217196</pubmed_id>
    </reference>
    <reference>
      <reference_text>Andersson B, Nyman PO, Strid L: Amino acid sequence of human erythrocyte carbonic anhydrase B.  Biochem Biophys Res Commun. 1972 Aug 7;48(3):670-7.</reference_text>
      <pubmed_id>4625868</pubmed_id>
    </reference>
    <reference>
      <reference_text>Lin KT, Deutsch HF: Human carbonic anhydrases. XI. The complete primary structure of carbonic anhydrase B. J Biol Chem. 1973 Mar 25;248(6):1885-93.</reference_text>
      <pubmed_id>4632246</pubmed_id>
    </reference>
    <reference>
      <reference_text>Lin KT, Deutsch HF: Human carbonic anhydrases. XII. The complete primary structure of the C isozyme. J Biol Chem. 1974 Apr 25;249(8):2329-37.</reference_text>
      <pubmed_id>4207120</pubmed_id>
    </reference>
    <reference>
      <reference_text>Briganti F, Mangani S, Scozzafava A, Vernaglione G, Supuran CT: Carbonic anhydrase catalyzes cyanamide hydration to urea: is it mimicking the physiological reaction? J Biol Inorg Chem. 1999 Oct;4(5):528-36.</reference_text>
      <pubmed_id>10550681</pubmed_id>
    </reference>
    <reference>
      <reference_text>Temperini C, Scozzafava A, Vullo D, Supuran CT: Carbonic anhydrase activators. Activation of isozymes I, II, IV, VA, VII, and XIV with l- and d-histidine and crystallographic analysis of their adducts with isoform II: engineering proton-transfer processes within the active site of an enzyme. Chemistry. 2006 Sep 18;12(27):7057-66.</reference_text>
      <pubmed_id>16807956</pubmed_id>
    </reference>
    <reference>
      <reference_text>Temperini C, Scozzafava A, Vullo D, Supuran CT: Carbonic anhydrase activators. Activation of isoforms I, II, IV, VA, VII, and XIV with L- and D-phenylalanine and crystallographic analysis of their adducts with isozyme II: stereospecific recognition within the active site of an enzyme and its consequences for the drug design. J Med Chem. 2006 May 18;49(10):3019-27.</reference_text>
      <pubmed_id>16686544</pubmed_id>
    </reference>
    <reference>
      <reference_text>Temperini C, Innocenti A, Scozzafava A, Mastrolorenzo A, Supuran CT: Carbonic anhydrase activators: L-Adrenaline plugs the active site entrance of isozyme II, activating better isoforms I, IV, VA, VII, and XIV. Bioorg Med Chem Lett. 2007 Feb 1;17(3):628-35. Epub 2006 Nov 15.</reference_text>
      <pubmed_id>17127057</pubmed_id>
    </reference>
    <reference>
      <reference_text>Crocetti L, Maresca A, Temperini C, Hall RA, Scozzafava A, Muhlschlegel FA, Supuran CT: A thiabendazole sulfonamide shows potent inhibitory activity against mammalian and nematode alpha-carbonic anhydrases. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1371-5. Epub 2009 Jan 19.</reference_text>
      <pubmed_id>19186056</pubmed_id>
    </reference>
    <reference>
      <reference_text>Maresca A, Temperini C, Vu H, Pham NB, Poulsen SA, Scozzafava A, Quinn RJ, Supuran CT: Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J Am Chem Soc. 2009 Mar 4;131(8):3057-62.</reference_text>
      <pubmed_id>19206230</pubmed_id>
    </reference>
    <reference>
      <reference_text>Di Fiore A, Monti SM, Hilvo M, Parkkila S, Romano V, Scaloni A, Pedone C, Scozzafava A, Supuran CT, De Simone G: Crystal structure of human carbonic anhydrase XIII and its complex with the inhibitor acetazolamide. Proteins. 2009 Jan;74(1):164-75.</reference_text>
      <pubmed_id>18618712</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kannan KK, Fridborg K, Bergsten PC, Liljas A, Lovgren S, Petef M, Strandberg B, Waara I, Adler L, Falkbring SO, Gothe PO, Nyman PO: Structure of human carbonic anhydrase B. I. Crystallization and heavy atom modifications. J Mol Biol. 1972 Feb 14;63(3):601-4.</reference_text>
      <pubmed_id>4622589</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kannan KK, Notstrand B, Fridborg K, Lovgren S, Ohlsson A, Petef M: Crystal structure of human erythrocyte carbonic anhydrase B. Three-dimensional structure at a nominal 2.2-A resolution. Proc Natl Acad Sci U S A. 1975 Jan;72(1):51-5.</reference_text>
      <pubmed_id>804171</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kannan KK, Ramanadham M, Jones TA: Structure, refinement, and function of carbonic anhydrase isozymes: refinement of human carbonic anhydrase I. Ann N Y Acad Sci. 1984;429:49-60.</reference_text>
      <pubmed_id>6430186</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kumar V, Kannan KK, Sathyamurthi P: Differences in anionic inhibition of human carbonic anhydrase I revealed from the structures of iodide and gold cyanide inhibitor complexes. Acta Crystallogr D Biol Crystallogr. 1994 Sep 1;50(Pt 5):731-8.</reference_text>
      <pubmed_id>15299369</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kumar V, Kannan KK: Enzyme-substrate interactions. Structure of human carbonic anhydrase I complexed with bicarbonate. J Mol Biol. 1994 Aug 12;241(2):226-32.</reference_text>
      <pubmed_id>8057362</pubmed_id>
    </reference>
    <reference>
      <reference_text>Chakravarty S, Kannan KK: Drug-protein interactions. Refined structures of three sulfonamide drug complexes of human carbonic anhydrase I enzyme. J Mol Biol. 1994 Oct 21;243(2):298-309.</reference_text>
      <pubmed_id>7932756</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ferraroni M, Tilli S, Briganti F, Chegwidden WR, Supuran CT, Wiebauer KE, Tashian RE, Scozzafava A: Crystal structure of a zinc-activated variant of human carbonic anhydrase I, CA I Michigan 1: evidence for a second zinc binding site involving arginine coordination. Biochemistry. 2002 May 21;41(20):6237-44.</reference_text>
      <pubmed_id>12009884</pubmed_id>
    </reference>
    <reference>
      <reference_text>Temperini C, Scozzafava A, Supuran CT: Carbonic anhydrase activators: the first X-ray crystallographic study of an adduct of isoform I. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5152-6. Epub 2006 Jul 25.</reference_text>
      <pubmed_id>16870440</pubmed_id>
    </reference>
    <reference>
      <reference_text>Jude KM, Banerjee AL, Haldar MK, Manokaran S, Roy B, Mallik S, Srivastava DK, Christianson DW: Ultrahigh resolution crystal structures of human carbonic anhydrases I and II complexed with &amp;quot;two-prong&amp;quot; inhibitors reveal the molecular basis of high affinity. J Am Chem Soc. 2006 Mar 8;128(9):3011-8.</reference_text>
      <pubmed_id>16506782</pubmed_id>
    </reference>
    <reference>
      <reference_text>Temperini C, Innocenti A, Guerri A, Scozzafava A, Rusconi S, Supuran CT: Phosph(on)ate as a zinc-binding group in metalloenzyme inhibitors: X-ray crystal structure of the antiviral drug foscarnet complexed to human carbonic anhydrase I. Bioorg Med Chem Lett. 2007 Apr 15;17(8):2210-5. Epub 2007 Feb 8.</reference_text>
      <pubmed_id>17314045</pubmed_id>
    </reference>
    <reference>
      <reference_text>Srivastava DK, Jude KM, Banerjee AL, Haldar M, Manokaran S, Kooren J, Mallik S, Christianson DW: Structural analysis of charge discrimination in the binding of inhibitors to human carbonic anhydrases I and II. J Am Chem Soc. 2007 May 2;129(17):5528-37. Epub 2007 Apr 4.</reference_text>
      <pubmed_id>17407288</pubmed_id>
    </reference>
    <reference>
      <reference_text>Omoto K, Ueda S, Goriki K, Takahashi N, Misawa S, Pagaran IG: Population genetic studies of the Philippine Negritos. III. Identification of the carbonic anhydrase-1 variant with CA1 Guam. Am J Hum Genet. 1981 Jan;33(1):105-11.</reference_text>
      <pubmed_id>6781336</pubmed_id>
    </reference>
    <reference>
      <reference_text>Chegwidden WR, Wagner LE, Venta PJ, Bergenhem NC, Yu YS, Tashian RE: Marked zinc activation of ester hydrolysis by a mutation, 67-His (CAT) to Arg (CGT), in the active site of human carbonic anhydrase I. Hum Mutat. 1994;4(4):294-6.</reference_text>
      <pubmed_id>7866410</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Methyclothiazide</name>
        <accession>HMDB14377</accession>
      </metabolite>
      <reference>
        <reference_text>Puscas I, Coltau M, Baican M, Domuta G, Hecht A: Vasodilatory effect of diuretics is dependent on inhibition of vascular smooth muscle carbonic anhydrase by a direct mechanism of action. Drugs Exp Clin Res. 1999;25(6):271-9.</reference_text>
        <pubmed_id>10713865</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methyclothiazide</name>
        <accession>HMDB14377</accession>
      </metabolite>
      <reference>
        <reference_text>Couloigner V, Loiseau A, Sterkers O, Amiel C, Ferrary E: Effect of locally applied drugs on the endolymphatic sac potential.  Laryngoscope. 1998 Apr;108(4 Pt 1):592-8.</reference_text>
        <pubmed_id>9546276</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methyclothiazide</name>
        <accession>HMDB14377</accession>
      </metabolite>
      <reference>
        <reference_text>Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. Epub 2008 Dec 24.</reference_text>
        <pubmed_id>19119014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethoxzolamide</name>
        <accession>HMDB14456</accession>
      </metabolite>
      <reference>
        <reference_text>Kohling R, Vreugdenhil M, Bracci E, Jefferys JG: Ictal epileptiform activity is facilitated by hippocampal GABAA receptor-mediated oscillations. J Neurosci. 2000 Sep 15;20(18):6820-9.</reference_text>
        <pubmed_id>10995826</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethoxzolamide</name>
        <accession>HMDB14456</accession>
      </metabolite>
      <reference>
        <reference_text>Perez Velazquez JL: Bicarbonate-dependent depolarizing potentials in pyramidal cells and interneurons during epileptiform activity. Eur J Neurosci. 2003 Sep;18(5):1337-42.</reference_text>
        <pubmed_id>12956733</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethoxzolamide</name>
        <accession>HMDB14456</accession>
      </metabolite>
      <reference>
        <reference_text>Heck RW, Tanhauser SM, Manda R, Tu C, Laipis PJ, Silverman DN: Catalytic properties of mouse carbonic anhydrase V.  J Biol Chem. 1994 Oct 7;269(40):24742-6.</reference_text>
        <pubmed_id>7929150</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethoxzolamide</name>
        <accession>HMDB14456</accession>
      </metabolite>
      <reference>
        <reference_text>Siffert W, Gros G: Carbonic anhydrase C in white-skeletal-muscle tissue.  Biochem J. 1982 Sep 1;205(3):559-66.</reference_text>
        <pubmed_id>6816217</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethoxzolamide</name>
        <accession>HMDB14456</accession>
      </metabolite>
      <reference>
        <reference_text>Scozzafava A, Briganti F, Ilies MA, Supuran CT: Carbonic anhydrase inhibitors: synthesis of membrane-impermeant low molecular weight sulfonamides possessing in vivo selectivity for the membrane-bound versus cytosolic isozymes. J Med Chem. 2000 Jan 27;43(2):292-300.</reference_text>
        <pubmed_id>10649985</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethoxzolamide</name>
        <accession>HMDB14456</accession>
      </metabolite>
      <reference>
        <reference_text>Bertucci A, Innocenti A, Zoccola D, Scozzafava A, Tambutte S, Supuran CT: Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8. Epub 2009 May 30.</reference_text>
        <pubmed_id>19520577</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methocarbamol</name>
        <accession>HMDB14567</accession>
      </metabolite>
      <reference>
        <reference_text>Parr JS, Khalifah RG: Inhibition of carbonic anhydrases I and II by N-unsubstituted carbamate esters.  J Biol Chem. 1992 Dec 15;267(35):25044-50.</reference_text>
        <pubmed_id>1460006</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bendroflumethiazide</name>
        <accession>HMDB14580</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bendroflumethiazide</name>
        <accession>HMDB14580</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Benzthiazide</name>
        <accession>HMDB14702</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Benzthiazide</name>
        <accession>HMDB14702</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cyclothiazide</name>
        <accession>HMDB14744</accession>
      </metabolite>
      <reference>
        <reference_text>Rammes G, Zeilhofer HU, Collingridge GL, Parsons CG, Swandulla D: Expression of early hippocampal CA1 LTP does not lead to changes in AMPA-EPSC kinetics or sensitivity to cyclothiazide. Pflugers Arch. 1999 Jan;437(2):191-6.</reference_text>
        <pubmed_id>9929558</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cyclothiazide</name>
        <accession>HMDB14744</accession>
      </metabolite>
      <reference>
        <reference_text>Rammes G, Swandulla D, Collingridge GL, Hartmann S, Parsons CG: Interactions of 2,3-benzodiazepines and cyclothiazide at AMPA receptors: patch clamp recordings in cultured neurones and area CA1 in hippocampal slices. Br J Pharmacol. 1996 Mar;117(6):1209-21.</reference_text>
        <pubmed_id>8882618</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cyclothiazide</name>
        <accession>HMDB14744</accession>
      </metabolite>
      <reference>
        <reference_text>Fleck MW, Bahring R, Patneau DK, Mayer ML: AMPA receptor heterogeneity in rat hippocampal neurons revealed by differential sensitivity to cyclothiazide. J Neurophysiol. 1996 Jun;75(6):2322-33.</reference_text>
        <pubmed_id>8793745</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cyclothiazide</name>
        <accession>HMDB14744</accession>
      </metabolite>
      <reference>
        <reference_text>Pirotte B, Podona T, Diouf O, de Tullio P, Lebrun P, Dupont L, Somers F, Delarge J, Morain P, Lestage P, Lepagnol J, Spedding M: 4H-1,2,4-Pyridothiadiazine 1,1-dioxides and 2,3-dihydro-4H-1,2, 4-pyridothiadiazine 1,1-dioxides chemically related to diazoxide and cyclothiazide as powerful positive allosteric modulators of (R/S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid receptors: design, synthesis, pharmacology, and structure-activity relationships. J Med Chem. 1998 Jul 30;41(16):2946-59.</reference_text>
        <pubmed_id>9685234</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cyclothiazide</name>
        <accession>HMDB14744</accession>
      </metabolite>
      <reference>
        <reference_text>Larson J, Le TT, Hall RA, Lynch G: Effects of cyclothiazide on synaptic responses in slices of adult and neonatal rat hippocampus. Neuroreport. 1994 Jan 12;5(4):389-92.</reference_text>
        <pubmed_id>8003661</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methazolamide</name>
        <accession>HMDB14841</accession>
      </metabolite>
      <reference>
        <reference_text>Ilies MA, Masereel B, Rolin S, Scozzafava A, Campeanu G, Cimpeanu V, Supuran CT: Carbonic anhydrase inhibitors: aromatic and heterocyclic sulfonamides incorporating adamantyl moieties with strong anticonvulsant activity. Bioorg Med Chem. 2004 May 15;12(10):2717-26.</reference_text>
        <pubmed_id>15110853</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methazolamide</name>
        <accession>HMDB14841</accession>
      </metabolite>
      <reference>
        <reference_text>Winum JY, Casini A, Mincione F, Starnotti M, Montero JL, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: N-(p-sulfamoylphenyl)-alpha-D-glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits. Bioorg Med Chem Lett. 2004 Jan 5;14(1):225-9.</reference_text>
        <pubmed_id>14684332</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methazolamide</name>
        <accession>HMDB14841</accession>
      </metabolite>
      <reference>
        <reference_text>Iyer GR, Bellantone RA, Taft DR: In vitro characterization of the erythrocyte distribution of methazolamide: a model of erythrocyte transport and binding kinetics. J Pharmacokinet Biopharm. 1999 Feb;27(1):45-66.</reference_text>
        <pubmed_id>10533697</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methazolamide</name>
        <accession>HMDB14841</accession>
      </metabolite>
      <reference>
        <reference_text>Scozzafava A, Briganti F, Ilies MA, Supuran CT: Carbonic anhydrase inhibitors: synthesis of membrane-impermeant low molecular weight sulfonamides possessing in vivo selectivity for the membrane-bound versus cytosolic isozymes. J Med Chem. 2000 Jan 27;43(2):292-300.</reference_text>
        <pubmed_id>10649985</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methazolamide</name>
        <accession>HMDB14841</accession>
      </metabolite>
      <reference>
        <reference_text>Lindskog S: Structure and mechanism of carbonic anhydrase.  Pharmacol Ther. 1997;74(1):1-20.</reference_text>
        <pubmed_id>9336012</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroflumethiazide</name>
        <accession>HMDB14912</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroflumethiazide</name>
        <accession>HMDB14912</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroflumethiazide</name>
        <accession>HMDB14912</accession>
      </metabolite>
      <reference>
        <reference_text>Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. Epub 2008 Dec 24.</reference_text>
        <pubmed_id>19119014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Acetazolamide</name>
        <accession>HMDB14957</accession>
      </metabolite>
      <reference>
        <reference_text>Puscas I, Coltau M, Pasca R: Nonsteroidal anti-inflammatory drugs activate carbonic anhydrase by a direct mechanism of action. J Pharmacol Exp Ther. 1996 Jun;277(3):1464-6.</reference_text>
        <pubmed_id>8667211</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Acetazolamide</name>
        <accession>HMDB14957</accession>
      </metabolite>
      <reference>
        <reference_text>Meierkord H, Grunig F, Gutschmidt U, Gutierrez R, Pfeiffer M, Draguhn A, Bruckner C, Heinemann U: Sodium bromide: effects on different patterns of epileptiform activity, extracellular pH changes and GABAergic inhibition. Naunyn Schmiedebergs Arch Pharmacol. 2000 Jan;361(1):25-32.</reference_text>
        <pubmed_id>10651143</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Acetazolamide</name>
        <accession>HMDB14957</accession>
      </metabolite>
      <reference>
        <reference_text>Puscas I, Ifrim M, Maghiar T, Coltau M, Domuta G, Baican M, Hecht A: Indomethacin activates carbonic anhydrase and antagonizes the effect of the specific carbonic anhydrase inhibitor acetazolamide, by a direct mechanism of action. Int J Clin Pharmacol Ther. 2001 Jun;39(6):265-70.</reference_text>
        <pubmed_id>11430635</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Acetazolamide</name>
        <accession>HMDB14957</accession>
      </metabolite>
      <reference>
        <reference_text>Puscas I, Coltau M, Baican M, Domuta G, Hecht A: Vasodilatory effect of diuretics is dependent on inhibition of vascular smooth muscle carbonic anhydrase by a direct mechanism of action. Drugs Exp Clin Res. 1999;25(6):271-9.</reference_text>
        <pubmed_id>10713865</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Acetazolamide</name>
        <accession>HMDB14957</accession>
      </metabolite>
      <reference>
        <reference_text>Perez Velazquez JL: Bicarbonate-dependent depolarizing potentials in pyramidal cells and interneurons during epileptiform activity. Eur J Neurosci. 2003 Sep;18(5):1337-42.</reference_text>
        <pubmed_id>12956733</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Acetazolamide</name>
        <accession>HMDB14957</accession>
      </metabolite>
      <reference>
        <reference_text>Mincione F, Scozzafava A, Supuran CT: The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. Curr Pharm Des. 2008;14(7):649-54.</reference_text>
        <pubmed_id>18336310</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dorzolamide</name>
        <accession>HMDB15007</accession>
      </metabolite>
      <reference>
        <reference_text>Hasegawa T, Hara K, Hata S: Binding of dorzolamide and its metabolite, N-deethylated dorzolamide, to human erythrocytes in vitro. Drug Metab Dispos. 1994 May-Jun;22(3):377-82.</reference_text>
        <pubmed_id>8070313</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dorzolamide</name>
        <accession>HMDB15007</accession>
      </metabolite>
      <reference>
        <reference_text>Maren TH, Conroy CW, Wynns GC, Levy NS: Ocular absorption, blood levels, and excretion of dorzolamide, a topically active carbonic anhydrase inhibitor. J Ocul Pharmacol Ther. 1997 Feb;13(1):23-30.</reference_text>
        <pubmed_id>9029437</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dorzolamide</name>
        <accession>HMDB15007</accession>
      </metabolite>
      <reference>
        <reference_text>Sugrue MF: The preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor. J Ocul Pharmacol Ther. 1996 Fall;12(3):363-76.</reference_text>
        <pubmed_id>8875343</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorothiazide</name>
        <accession>HMDB15018</accession>
      </metabolite>
      <reference>
        <reference_text>Puscas I, Coltau M, Baican M, Domuta G, Hecht A: Vasodilatory effect of diuretics is dependent on inhibition of vascular smooth muscle carbonic anhydrase by a direct mechanism of action. Drugs Exp Clin Res. 1999;25(6):271-9.</reference_text>
        <pubmed_id>10713865</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorothiazide</name>
        <accession>HMDB15018</accession>
      </metabolite>
      <reference>
        <reference_text>Puscas I, Coltau M, Baican M, Pasca R, Domuta G: The inhibitory effect of diuretics on carbonic anhydrases.  Res Commun Mol Pathol Pharmacol. 1999;105(3):213-36.</reference_text>
        <pubmed_id>10954127</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>De Simone G, Di Fiore A, Menchise V, Pedone C, Antel J, Casini A, Scozzafava A, Wurl M, Supuran CT: Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorg Med Chem Lett. 2005 May 2;15(9):2315-20.</reference_text>
        <pubmed_id>15837316</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity.  Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92.</reference_text>
        <pubmed_id>18537527</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Shank RP, Smith-Swintosky VL, Maryanoff BE: Carbonic anhydrase inhibition. Insight into the characteristics of zonisamide, topiramate, and the sulfamide cognate of topiramate. J Enzyme Inhib Med Chem. 2008 Apr;23(2):271-6.</reference_text>
        <pubmed_id>18343915</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Masuda Y, Karasawa T: Inhibitory effect of zonisamide on human carbonic anhydrase in vitro.  Arzneimittelforschung. 1993 Apr;43(4):416-8.</reference_text>
        <pubmed_id>8494570</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders.  Mini Rev Med Chem. 2008 Sep;8(10):968-75.</reference_text>
        <pubmed_id>18782051</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Temperini C, Cecchi A, Boyle NA, Scozzafava A, Cabeza JE, Wentworth P Jr, Blackburn GM, Supuran CT: Carbonic anhydrase inhibitors. Interaction of 2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies. Bioorg Med Chem Lett. 2008 Feb 1;18(3):999-1005. Epub 2007 Dec 15.</reference_text>
        <pubmed_id>18162396</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Biton V: Clinical pharmacology and mechanism of action of zonisamide.  Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40.</reference_text>
        <pubmed_id>17762320</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>[No authors listed]Zonisamide: new drug. No advantage in refractory partial epilepsy.  Prescrire Int. 2007 Jun;16(89):95-7.</reference_text>
        <pubmed_id>17582922</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trichlormethiazide</name>
        <accession>HMDB15156</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trichlormethiazide</name>
        <accession>HMDB15156</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trichlormethiazide</name>
        <accession>HMDB15156</accession>
      </metabolite>
      <reference>
        <reference_text>Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. Epub 2008 Dec 24.</reference_text>
        <pubmed_id>19119014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethinamate</name>
        <accession>HMDB15165</accession>
      </metabolite>
      <reference>
        <reference_text>Parr JS, Khalifah RG: Inhibition of carbonic anhydrases I and II by N-unsubstituted carbamate esters.  J Biol Chem. 1992 Dec 15;267(35):25044-50.</reference_text>
        <pubmed_id>1460006</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diazoxide</name>
        <accession>HMDB15251</accession>
      </metabolite>
      <reference>
        <reference_text>Domoki F, Bari F, Nagy K, Busija DW, Siklos L: Diazoxide prevents mitochondrial swelling and Ca2+ accumulation in CA1 pyramidal cells after cerebral ischemia in newborn pigs. Brain Res. 2004 Sep 3;1019(1-2):97-104.</reference_text>
        <pubmed_id>15306243</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diazoxide</name>
        <accession>HMDB15251</accession>
      </metabolite>
      <reference>
        <reference_text>Erdemli G, Krnjevic K: Diazoxide suppresses slowly-inactivating outward and inward currents in CA1 hippocampal neurones. Neuroreport. 1993 Dec 13;5(3):249-51.</reference_text>
        <pubmed_id>8298083</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diazoxide</name>
        <accession>HMDB15251</accession>
      </metabolite>
      <reference>
        <reference_text>Erdemli G, Krnjevic K: Actions of diazoxide on CA1 neurons in hippocampal slices from rats.  Can J Physiol Pharmacol. 1995 May;73(5):608-18.</reference_text>
        <pubmed_id>7585327</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diazoxide</name>
        <accession>HMDB15251</accession>
      </metabolite>
      <reference>
        <reference_text>Scuvee-Moreau J, Seutin V, Vrijens B, Pirotte B, De Tullio P, Massotte L, Albert A, Delarge J, Dresse A: Effect of potassium channel openers on the firing rate of hippocampal pyramidal cells and A10 dopaminergic neurons in vitro. Arch Physiol Biochem. 1997 Sep;105(5):421-8.</reference_text>
        <pubmed_id>9439778</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diazoxide</name>
        <accession>HMDB15251</accession>
      </metabolite>
      <reference>
        <reference_text>Crepel V, Rovira C, Ben-Ari Y: The K+ channel opener diazoxide enhances glutamatergic currents and reduces GABAergic currents in hippocampal neurons. J Neurophysiol. 1993 Feb;69(2):494-503.</reference_text>
        <pubmed_id>7681475</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dichlorphenamide</name>
        <accession>HMDB15275</accession>
      </metabolite>
      <reference>
        <reference_text>Winum JY, Casini A, Mincione F, Starnotti M, Montero JL, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: N-(p-sulfamoylphenyl)-alpha-D-glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits. Bioorg Med Chem Lett. 2004 Jan 5;14(1):225-9.</reference_text>
        <pubmed_id>14684332</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dichlorphenamide</name>
        <accession>HMDB15275</accession>
      </metabolite>
      <reference>
        <reference_text>Lindskog S: Structure and mechanism of carbonic anhydrase.  Pharmacol Ther. 1997;74(1):1-20.</reference_text>
        <pubmed_id>9336012</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dichlorphenamide</name>
        <accession>HMDB15275</accession>
      </metabolite>
      <reference>
        <reference_text>Nishimori I, Minakuchi T, Onishi S, Vullo D, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors. J Med Chem. 2007 Jan 25;50(2):381-8.</reference_text>
        <pubmed_id>17228881</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dichlorphenamide</name>
        <accession>HMDB15275</accession>
      </metabolite>
      <reference>
        <reference_text>Giacomotto J, Pertl C, Borrel C, Walter MC, Bulst S, Johnsen B, Baillie DL, Lochmuller H, Thirion C, Segalat L: Evaluation of the therapeutic potential of carbonic anhydrase inhibitors in two animal models of dystrophin deficient muscular dystrophy. Hum Mol Genet. 2009 Nov 1;18(21):4089-101. Epub 2009 Jul 31.</reference_text>
        <pubmed_id>19648295</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dichlorphenamide</name>
        <accession>HMDB15275</accession>
      </metabolite>
      <reference>
        <reference_text>Cleland JC, Griggs RC: Treatment of neuromuscular channelopathies: current concepts and future prospects. Neurotherapeutics. 2008 Oct;5(4):607-12.</reference_text>
        <pubmed_id>19019313</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Brinzolamide</name>
        <accession>HMDB15325</accession>
      </metabolite>
      <reference>
        <reference_text>Winum JY, Casini A, Mincione F, Starnotti M, Montero JL, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: N-(p-sulfamoylphenyl)-alpha-D-glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits. Bioorg Med Chem Lett. 2004 Jan 5;14(1):225-9.</reference_text>
        <pubmed_id>14684332</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Brinzolamide</name>
        <accession>HMDB15325</accession>
      </metabolite>
      <reference>
        <reference_text>Herkel U, Pfeiffer N: Update on topical carbonic anhydrase inhibitors.  Curr Opin Ophthalmol. 2001 Apr;12(2):88-93.</reference_text>
        <pubmed_id>11224713</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinethazone</name>
        <accession>HMDB15420</accession>
      </metabolite>
      <reference>
        <reference_text>Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Sulfonamide diuretics revisited--old leads for new applications? Org Biomol Chem. 2008 Jul 21;6(14):2499-506. Epub 2008 May 29.</reference_text>
        <pubmed_id>18600270</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinethazone</name>
        <accession>HMDB15420</accession>
      </metabolite>
      <reference>
        <reference_text>Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct. Bioorg Med Chem Lett. 2008 Apr 15;18(8):2567-73. Epub 2008 Mar 20.</reference_text>
        <pubmed_id>18374572</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinethazone</name>
        <accession>HMDB15420</accession>
      </metabolite>
      <reference>
        <reference_text>Supuran CT: Diuretics: from classical carbonic anhydrase inhibitors to novel applications of the sulfonamides. Curr Pharm Des. 2008;14(7):641-8.</reference_text>
        <pubmed_id>18336309</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
